v3.25.4
Shareholders' Equity - Share options and restricted stock units (Details)
12 Months Ended
Dec. 31, 2025
EUR (€)
EquityInstruments
Y
tranche
Dec. 31, 2024
EUR (€)
EquityInstruments
Y
Dec. 31, 2023
EUR (€)
EquityInstruments
Y
Shareholders Equity      
Compensation expenses € 4,014,000 € 2,544,000  
Number of other equity instruments granted in share-based payment arrangement | EquityInstruments     52,319
Research and development costs      
Shareholders Equity      
Compensation expenses 1,166,000 560,000  
IFRS General and administrative costs      
Shareholders Equity      
Compensation expenses € 2,848,000 € 1,984,000  
Share options and restricted stock units | Four years vesting period with 25% vesting every year      
Shareholders Equity      
Vesting period 4 years    
Annual vesting percentage 25.00%    
Share options and restricted stock units | Four years vesting in thirteen tranches      
Shareholders Equity      
Vesting period 4 years    
Number of tranches | tranche 13    
Number of Remaining Tranches after First Anniversary of Grant Date | tranche 12    
Quarterly vesting percentage after first tranche is vested 6.25%    
Share options and restricted stock units | Two years vesting period with 25% vesting every six months      
Shareholders Equity      
Vesting period 2 years    
Biannual vesting percentage 25.00%    
Share options      
Shareholders Equity      
Vesting period 4 years    
Options, contractual term 10 years    
Period following grant date that options are assumed to be exercised 7 years    
Risk-free interest rate 4.099% 3.903% 3.96%
Expected volatility 101.50% 96.50% 105.60%
Expected life in years | Y 5 5 5
Restricted stock units      
Shareholders Equity      
Weighted average fair value at measurement date, other equity instruments granted     € 2.76
Number of other equity instruments granted in share-based payment arrangement | EquityInstruments 0 0